2025 Conjugate Vaccine Market Outlook: Key Indicators Shaping Growth Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Conjugate Vaccine Industry Market Size Be by 2025?
In recent times, the conjugate vaccine market has seen expeditious growth. The market size is projected to rise from $18.9 billion in 2024 to $21.46 billion in 2025, at a compound annual growth rate (CAGR) of 13.5%. The augmentation during the previous period is credited to factors such as disease prevalence, government-led immunization schemes, heightened awareness, a priority on pediatric vaccination, and a focus on preventive healthcare trends.

What's the Long-Term Growth Forecast for the Conjugate Vaccine Market Size Through 2029?
The conjugate vaccine market is anticipated to experience swift expansion in the coming years, culminating in a value of "$34.59 billion by 2029 at a compound annual growth rate (CAGR) of 12.7%. Factors contributing to this projected growth in the stipulated period include broader vaccination strategies, modifications in the aging population, new vaccine indications, worldwide health safety matters, international collaboration, and the impact of economic development. The period is also expected to witness major trends like partnerships for distributing vaccines, custom strategies for populations at high risk, application towards emerging infectious diseases, developments in vaccine manufacturing technologies and global health drives advocating for vaccine fairness.

View the full report here:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Are the Key Growth Drivers Fueling the Conjugate Vaccine Market Expansion?
The surge in the utilization of conjugate vaccines among adults is set to fuel the expansion of the conjugate vaccine market. Conjugate vaccines are specifically crafted to trigger a potent immune reaction against bacterial capsular polysaccharides, thereby boosting the body's resistance to bacterial infections. The employment of these vaccines in adults serves to lower the possibility of severe sickness, complications, and spreading of these bacterial diseases by inciting a powerful immune response. For example, in June 2024, data from the UK Health Security Agency (UKHSA), a public health organization based in the UK, revealed that the 12-month coverage for the '6-in-1' vaccine in the UK remained steady at 91.7%. The pneumococcal conjugate vaccine's (PCV) initial dose also stayed at 93.7%. Meanwhile, Rotavirus coverage experienced a 0.6% uptick, touching 89.3%, and the second dose of the meningitis B vaccine (MenB2) inched up by 0.1% to 91.5%. As such, the rise in the employment of conjugate vaccines for adults is bolstering the expansion of the conjugate vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

What Are the Key Trends Driving Conjugate Vaccine Market Growth?
Companies in the conjugate vaccine market are strengthening their market position through innovative approaches to conjugate vaccine development. For instance, the introduction of the pneumococcal 20-valent conjugate vaccine named Prevnar 20 by Pfizer Inc., a pharmaceutical and biotechnology firm headquartered in the USA, is a key trend that became prominent in June 2022. This vaccine was launched in Canada for the prevention of pneumonia and invasive pneumococcal infections in adults above the age of 18. Aside from the 13 serotypes already covered by PREVNAR 13, Prevnar 20 also includes conjugates for seven more serotypes that are linked to invasive pneumococcal disease, high mortality rates, antibiotic resistance, and meningitis. This signifies a major advancement in the field of conjugate vaccines.

How Is the Conjugate Vaccine Market Segmented?
The conjugate vaccine market covered in this report is segmented -

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:
1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines
2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

Which Companies Are Leading the Charge in Conjugate Vaccine Market Innovation?
Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Which Regions Are Leading the Global Conjugate Vaccine Market in Revenue?
North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.